Article Details
Retrieved on: 2025-03-09 23:01:54
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here